Patents by Inventor John Warren Thomas
John Warren Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7091319Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.Type: GrantFiled: June 6, 1995Date of Patent: August 15, 2006Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Marie Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Publication number: 20040018618Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceuical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial experession systems. Included in the presnt invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a. 119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.Type: ApplicationFiled: June 19, 2002Publication date: January 29, 2004Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Olins, Kumnan Paik, Joseph Polazzi, John Warren Thomas
-
Publication number: 20030220472Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems.Type: ApplicationFiled: February 19, 2002Publication date: November 27, 2003Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 6479261Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.Type: GrantFiled: November 15, 1995Date of Patent: November 12, 2002Assignee: Pharmacia CorporationInventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Olins, Kumnan Paik, Joseph Polazzi, John Warren Thomas
-
Patent number: 6458931Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.Type: GrantFiled: June 6, 1995Date of Patent: October 1, 2002Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Bradford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 6403076Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.Type: GrantFiled: June 6, 1995Date of Patent: June 11, 2002Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Marie Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Q Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 6132991Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.Type: GrantFiled: June 6, 1995Date of Patent: October 17, 2000Assignee: G. D. Searle & Co.Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 6074639Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.Type: GrantFiled: November 15, 1995Date of Patent: June 13, 2000Assignee: G. D. Searle & Co.Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 6057133Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin, hematopoietic growth factor or IL-3 variant. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.Type: GrantFiled: February 4, 1994Date of Patent: May 2, 2000Assignee: G. D. SearleInventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 5997860Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.Type: GrantFiled: November 15, 1995Date of Patent: December 7, 1999Assignee: G. D. Searle & Co.Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 5997857Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.Type: GrantFiled: June 6, 1995Date of Patent: December 7, 1999Assignee: G. D. Searle & Co.Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 5858347Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.Type: GrantFiled: June 6, 1995Date of Patent: January 12, 1999Assignee: G. D. Searle & Co.Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 5772992Abstract: The invention provides compositions comprising a human interleukin-3 (hIL-3) variant or mutant protein (mutein) and another colony stimulating factor, cytokine, lymphokine, interleukin, or hematopoietic growth factor. The compositions are useful for the therapeutic co-administration of the proteins, as for example in hematopoietic reconstitution. factors or IL-3 variants.Type: GrantFiled: February 4, 1994Date of Patent: June 30, 1998Assignee: G.D. Searle & Co.Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 5738849Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.Type: GrantFiled: February 4, 1994Date of Patent: April 14, 1998Assignee: G. D. Searle & Co.Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
-
Patent number: 5677149Abstract: Disclosed are recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins) having one to three amino acid substitutions in the core sequence (residues 15-125) of the native (133 amino acid) sequence of hIL-3. The muteins of the invention may also have deletions of 1 to 14 amino acids at the N-terminus and/or 1 to 15 amino acids at the C-terminus relative to the native hIL-3 sequence. Also within the scope of the invention are recombinant expression systems and methods for making the mutant hIL-3 polypeptides, as well as pharmaceutical compositions and methods for using them. The disclosed hIL-3 mutant polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile in therapeutic applications.Type: GrantFiled: April 6, 1995Date of Patent: October 14, 1997Assignee: G.D. Searle & Co.,Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Olins, Kumnan Paik, Joseph Polazzi, John Warren Thomas